These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 17310821

  • 1. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS.
    Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
    [Abstract] [Full Text] [Related]

  • 2. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA.
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [Abstract] [Full Text] [Related]

  • 3. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.
    Santantonio T, Fasano M, Durantel S, Barraud L, Heichen M, Guastadisegni A, Pastore G, Zoulim F.
    Antivir Ther; 2009 Dec; 14(4):557-65. PubMed ID: 19578241
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J.
    J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
    [Abstract] [Full Text] [Related]

  • 5. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML.
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [Abstract] [Full Text] [Related]

  • 6. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS.
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [Abstract] [Full Text] [Related]

  • 7. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H.
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [Abstract] [Full Text] [Related]

  • 8. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H.
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [Abstract] [Full Text] [Related]

  • 9. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM.
    Antivir Ther; 2012 Jun; 17(4):701-9. PubMed ID: 22358132
    [Abstract] [Full Text] [Related]

  • 10. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM, Park JY, Kim DY, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH.
    Antivir Ther; 2010 Jun; 15(2):235-41. PubMed ID: 20386079
    [Abstract] [Full Text] [Related]

  • 11. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, Shiina M, Kondo Y, Kakazu E, Tamai K, Obara N, Iwasaki T, Shimosegawa T.
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [Abstract] [Full Text] [Related]

  • 12. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
    Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J.
    J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
    [Abstract] [Full Text] [Related]

  • 13. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.
    Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, Byun KS, Lee CH.
    Gut; 2006 Oct; 55(10):1488-95. PubMed ID: 16461777
    [Abstract] [Full Text] [Related]

  • 14. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL.
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [Abstract] [Full Text] [Related]

  • 15. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim SO, Yoo WD, Cho SW.
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [Abstract] [Full Text] [Related]

  • 16. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group.
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [Abstract] [Full Text] [Related]

  • 17. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
    Akman SA, Kose S, Halicioglu O.
    Int J Infect Dis; 2010 Mar; 14(3):e236-9. PubMed ID: 19665408
    [Abstract] [Full Text] [Related]

  • 18. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C.
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [Abstract] [Full Text] [Related]

  • 19. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.